Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1055004


Croatia Pharmaceuticals and Healthcare Report Q3 2009


Description: Croatia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulartory bodies with independent forecasts and competitive intelligence on Croatia's pharmaceutical and healthcare industry

Of the 20 markets measured in BMI’s Q309 Pharmaceuticals & Healthcare Business Environment Rankings for Central and Eastern Europe (CEE), Croatia is placed 10th, reflecting the country’s middleranking attractiveness for multinational companies. While the Croatian market is making great efforts to align regulations with EU guidelines, the market still holds certain drawbacks for companies looking to enter. The Croatian pharmaceutical market is in itself not overly high in value compared with many of its CEE counterparts, with per capita spending calculated to have reached a mere US$178 in 2008. Through to 2013 BMI forecasts compound growth rate (CAGR) for drug expenditure in Croatia will be 5.76% in local currency terms, reflecting a stable level of expansion, albeit below many of the emerging CEE markets.

Legislative improvements and future EU accession should prove a great attraction to pharmaceutical companies in future; however, there are still some potential drawbacks for the Croatian system, particularly in terms of a preference for local generics manufacturers. While budget restraints have limited widespread access to modern treatments, a steady stream of patented pharmaceuticals have been made available for reimbursement. The most recent additions to this list include GlaxoSmithKline (GSK)’s non-small lung cancer treatment Tarceva (erlotinib) and Pfizer’s kidney cancer drug Sutent (sunitinib). Nevertheless, as a result of the implementation of tendering systems for medicines, as part of recent procurements the HZZO has saved close to US$67mn. Drugmakers have been forced to cut prices by an average of 12% in order to remain providers for drugs on the reimbursement list, with patented drugmakers having to make the largest concessions.

For 2009 the Ministry of Health has increased its budget for drugs to HRK3.1bn, which should provide a boost to prescription sales, reinforcing our view that the prescription market will remain resilient to the economic downturn. However, we are slightly less optimistic for the over-the-counter (OTC) market, which is likely to witness some downturn as a result of a contraction in spending, which may further result in reductions in spending on less essential medicines.

Over the longer term, however, it is our view that OTCs will continue to prosper at the expense of the prescription market share. The expansion of the number of outlets where OTC medicines are available, combined with a general increase in self-medication should continue to drive growth in the sector. Meanwhile advertising – which is permitted in all major forms for OTCs – should help create brand value for high potential products.


Contents: Executive Summary
Croatia Pharmaceuticals Industry SWOT
Croatia Political SWOT
Croatia Economic SWOT
Croatia Business Environment SWOT

Pharmaceutical Business Environment Ratings
Table: Regional Pharma Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns

Croatia – Market Summary

Regulatory Regime
Intellectual Property Regime
Pricing Regime
Reimbursement Regime
Recent Pricing And Reimbursement Developments
OTC Regulations

Industry Trends And Developments
Epidemiology
Table: Disease Burden In CEE
Healthcare Provision
Healthcare Expenditure
Healthcare Debts
Healthcare Reform
Domestic Pharmaceutical Industry
Domestic Company Activity
Foreign Company Activity
Table: Lukaps’ Time Line
Pharmaceutical Retail
Research And Development Sector
Clinical Trials
Medical Devices

Industry Forecast Scenario
Overall Market Forecast
Table: Croatia – Drug Expenditure Indicators, Historical Data and Forecasts
Key Growth Factors – Industry
Table: Croatia – Health Expenditure Indicators, Historical Data and Forecasts
Key Growth Factors – Macroeconomic
Table: Croatia - Economic Activity, 2005-2013
Prescription Market Forecast
Table: Croatia – Prescription Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated)
Patented Market Forecast
Table: Croatia – Patented Market Indicators, Historical Data and Forecasts
Generics Market Forecast
Table: Croatia – Generics Market Indicators, Historical Data and Forecasts
OTC Market Forecast
Table: Croatia – OTC Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated)
Export/Import Forecasts
Table: Croatia – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn)
Other Healthcare Forecasts
Table: Croatia – Other Healthcare Indicators, Historical Data and Forecasts
Key Risks To BMI’s Forecast Scenario

Competitive Landscape

Company Monitor
International Company Profiles
GlaxoSmithKline
Pfizer
Sanofi-Aventis
Novartis
Merck & Co
Krka
Indigenous Company Profiles
Pliva
Belupo

Country Snapshot: Croatia Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2000-2003
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 1999-2004
Table: Consumer Expenditure, 2000-2010 (US$)
Table: Average Annual Wages, 2000-2010

BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Companies Mentioned - GlaxoSmithKline - Pfizer - Sanofi-Aventis - Novartis - Merck & Co - Krka - Pliva - Belupo


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/1055004

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 15/02/2012 22:49:42
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Croatia Pharmaceuticals and Healthcare Report Q3 2009
Web Address:
http://www.researchandmarkets.com/reports/1055004
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €393.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 15/02/2012 22:49:42

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)